India Tuberculosis Vaccine Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the India Tuberculosis Vaccine Market was valued at USD 554.0 million in 2025 and is projected to reach USD 784.75 million by 2032, growing at a CAGR of approximately 5.1% during 2026–2032.
India Tuberculosis Vaccine Market Highlights
| Report Metric | Details |
| Report Name | India Tuberculosis Vaccine Market |
| Market Size 2025 | USD 554.0 million |
| Market Size 2032 | USD 784.75 million |
| Absolute Growth 2025–2032 | USD 230.75 million |
| CAGR 2026–2032 | 5.1% |
| Peak Annual Growth | 7.1% in 2030 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Vaccine Type, 2025 | BCG Vaccine (41% share) |
| Leading Formulation Type, 2025 | Live Attenuated (37% share) |
| Leading Delivery Mode, 2025 | Intradermal Injection (35% share) |
| Leading End User, 2025 | Public Health Programs (48% share) |
| Fastest-Growing Vaccine Type | Recombinant TB Vaccine (7.4% CAGR) |
| Fastest-Growing Formulation Type | Protein Subunit (6.9% CAGR) |
| Fastest-Growing Delivery Mode | Clinical Trials (6.2% CAGR) |
| Fastest-Growing End User | Biotech Firms (7.2% CAGR) |
| Growing Sector | Public Health Programs |
| Key End Users | Hospitals, Public Health Programs, Biotech Firms, Pharma Researchers |
India Tuberculosis Vaccine Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
The table below sets out the estimated growth rate for each year and the main factor behind it.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 6.3 | The market demonstrated strong demand due to high TB case numbers and vaccination efforts. |
| 2023 | 4.0 | Growth slowed as vaccination campaigns faced logistical challenges in rural areas. |
| 2024 | 3.1 | Continued efforts in public health programs led to further but slower growth. |
| 2025 | 3.8 | Increased funding for TB control measures boosted vaccination rates. |
| 2026 | 3.2 | Growth slowed as market adjustments occurred following previous expansions. |
| 2027 | 4.7 | Rising investments in vaccine research and development spurred demand. |
| 2028 | 5.9 | Public health initiatives continued to drive demand for TB vaccinations. |
| 2029 | 3.7 | Growth slowed as the market stabilised after previous peaks. |
| 2030 | 7.1 | A surge in vaccination campaigns led to the highest growth rate. |
| 2031 | 6.3 | Demand normalised as vaccination efforts reached broader populations. |
| 2032 | 4.9 | Growth slowed as the market approaches maturity with established programs. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
India Tuberculosis Vaccine Market Synopsis
The Tuberculosis Vaccine Market in India includes the Bacillus Calmette-Guérin (BCG) strain, which is primarily used to prevent tuberculosis in infants and young children. Produced through laboratory culturing, this vaccine plays a crucial role in public health initiatives. The market is expanding due to the National Tuberculosis Elimination Program, which aims to eradicate TB by 2025, alongside the distribution of over 80 million doses each year. The alarming number of TB cases reported in 2022, surpassing 2.5 million, highlights the pressing need for vaccination efforts.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Increased government funding for TB control initiatives | Driver | High | Public Health Programs |
| Growing public awareness of tuberculosis prevention | Driver | High | Hospitals |
| Rising demand for innovative vaccine formulations | Opportunity | Medium | Recombinant TB Vaccine |
| Expansion of clinical trials for new TB vaccines | Opportunity | Medium | Clinical Trials |
| Challenges in vaccine distribution in rural areas | Restraint | High | BCG Vaccine |
| Limited availability of new vaccine candidates | Restraint | Medium | Recombinant TB Vaccine |
| Supply chain disruptions affecting vaccine availability | Challenge | High | BCG Vaccine |
| Regulatory hurdles for new vaccine approvals | Challenge | Medium | Recombinant TB Vaccine |
Evaluation of Drivers in India Tuberculosis Vaccine Market (2026–2032)
The factors lifting demand, and the evidence behind each, are summarised below.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Increased government funding for TB control initiatives | Public Health Programs | The Indian government allocated 1 billion INR specifically for TB control measures in 2021, boosting vaccination efforts. |
| Growing public awareness of tuberculosis prevention | Hospitals | Public health campaigns have increased knowledge, leading to more hospital vaccinations for TB, especially given the high incidence of cases. |
| Rising demand for new vaccine formulations | Recombinant TB Vaccine | The National Tuberculosis Elimination Program encourages the development of new vaccine candidates, driving market interest. |
| Expansion of clinical trials for new TB vaccines | Clinical Trials | Ongoing clinical trials in research institutions are vital for developing new TB vaccines and increasing market options. |
| High incidence of tuberculosis cases | BCG Vaccine | Over 2.5 million TB cases reported in 2022 highlight the urgent need for vaccination. |
Market growth in India for Tuberculosis Vaccine rests on increased government funding, public awareness, and the demand for new vaccine formulations. The Indian government allocated 1 billion INR specifically for TB control measures in 2021, boosting vaccination efforts. Public health campaigns have raised knowledge, leading to increased hospital vaccinations for TB, especially with over 2.5 million cases reported in 2022. The National Tuberculosis Elimination Program encourages the development of new vaccine candidates, while ongoing clinical trials in research institutions are essential for expanding options. These factors drive demand for the BCG vaccine, vital for preventing tuberculosis in infants and young children.
Evaluation of Restraints in India Tuberculosis Vaccine Market
The main factors holding the market back are set out below.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| Challenges in vaccine distribution in rural areas | BCG Vaccine | Logistical issues in rural regions hinder effective vaccine distribution, affecting overall vaccination rates. |
| Limited availability of new vaccine candidates | Recombinant TB Vaccine | Research and development delays slow the introduction of new vaccines into the market. |
| Supply chain disruptions affecting vaccine availability | BCG Vaccine | Supply chain issues have led to shortages, impacting vaccination programs across the country. |
| Regulatory hurdles for new vaccine approvals | Recombinant TB Vaccine | Stringent regulations delay the approval process for new TB vaccines, affecting market growth. |
| Inadequate healthcare infrastructure in some regions | BCG Vaccine | Poor healthcare infrastructure limits access to vaccination services, particularly in remote areas. |
India Tuberculosis Vaccine Market Challenges
Producers in the India tuberculosis vaccine market face a skills shortage, as the limited number of specialised training programs fails to equip enough personnel, delaying vaccine production timelines. High operational costs arise from the need for compliance with ISO 9001:2015 certification, increasing expenses for manufacturers and ultimately raising prices for hospitals. Competition from emerging TB vaccine candidates pressures suppliers to invest heavily in research and development, diverting funds from existing production capabilities and impacting the availability of current vaccines. Technological advancements in vaccine delivery methods are slow to be adopted, forcing producers to rely on outdated techniques that may not meet evolving healthcare standards.
Trends in the India Tuberculosis Vaccine Market
Below mentioned are some of the trends shaping the India Tuberculosis Vaccine Market growth.
- Shift from Traditional to Innovative Vaccine Development: Since 2020, there has been a notable shift towards innovative vaccine development in India, particularly with the 'TB Mukt Bharat' initiative. This initiative aims to improve TB control efforts and has led to increased funding for research, with over 1 billion INR allocated for new vaccine candidates.
- Increase in Public Health Campaigns: Public health programs have intensified awareness campaigns since 2020, significantly impacting vaccination rates. For instance, the National Health Mission has distributed over 80 million doses of the BCG vaccine annually, showcasing the effectiveness of these campaigns.
- Growth in Clinical Trials for New Vaccines: The number of clinical trials for new TB vaccines has surged since 2023, with several research institutions actively participating. This growth is supported by the Indian Council of Medical Research, which initiated a program focusing on innovative delivery methods.
- Focus on Intradermal Delivery Methods: Intradermal injection has become the primary delivery mode for the BCG vaccine, with ongoing research aimed at improving its efficacy. The Central Drugs Standard Control Organization has updated guidelines to support this delivery method, ensuring compliance with safety standards.
Investment Opportunities in the India Tuberculosis Vaccine Market
Several openings in the India Tuberculosis Vaccine Market merit attention from investors.
- Public Health Programs Seeking Effective Vaccines: Public health programs in India require effective TB vaccines, with over 80 million doses distributed annually. Suppliers can enter this market by collaborating with local health agencies to improve vaccine delivery.
- Growing Demand for Innovative Vaccine Formulations: With a projected market size of USD 784.75 million by 2032, there is a notable gap for innovative TB vaccines. Biotech firms can invest in research collaborations to develop new candidates.
- Clinical Trials for New TB Vaccines: The ongoing clinical trials for new TB vaccines present a unique opportunity, with several institutions involved. Investors can engage through joint ventures with research facilities to support these trials.
- Expansion of TB Control Initiatives: The 'TB Mukt Bharat' initiative has allocated substantial funding for TB control, creating opportunities for suppliers. Entering through local partnerships can facilitate access to government contracts.
Government Initiatives in the India Tuberculosis Vaccine Market
The National Tuberculosis Elimination Program, launched by the Ministry of Health and Family Welfare in 2020, aims to eliminate TB by 2025 through enhanced vaccination and treatment strategies. This program builds on earlier efforts to control tuberculosis and broadens the scope of vaccination initiatives across India. It underscores the importance of public health programs in combating TB and ensures that vaccination remains a priority in healthcare strategies. The program's funding and resources are crucial for achieving national health targets, particularly in high-risk populations. By integrating vaccination with treatment, the program improves the overall effectiveness of TB control measures.
The Central Drugs Standard Control Organization oversees vaccine approvals and safety standards, ensuring compliance with regulations. This agency plays a critical role in facilitating the introduction of new TB vaccines into the market. It funds research initiatives aimed at developing innovative vaccine candidates and supports clinical trials conducted by various institutions. The agency's updated approval pathways, established in 2022, expedite the process for new vaccines, creating a more dynamic vaccine development environment. By streamlining these processes, the agency improves the availability of vaccines for public health programs.
Future Insight of the India Tuberculosis Vaccine Market
By 2032, buyers and suppliers in the India tuberculosis vaccine market can expect transformative changes driven by government initiatives and ongoing research collaborations. The National Tuberculosis Elimination Program aims to significantly enhance vaccination coverage, targeting the eradication of TB by 2025. Public health programs are projected to distribute over 80 million doses annually, reflecting a strong commitment to vaccination efforts. New research collaborations will pave the way for next-generation vaccines, positioning India as a key player in global tuberculosis control initiatives.
Market Segmentation Analysis
Each segment group is reviewed below, with the leader by share and the fastest grower by CAGR.
By Vaccine Type – BCG Vaccine Dominated, Recombinant TB Vaccine Expected to Grow Fastest
According to Vasudha, AM at 6Wresearch, the largest vaccine type category in 2025 was BCG Vaccine, with a 41% share of total revenue. The BCG Vaccine holds the largest market share as it is integral to India's National Immunization Program, administered to newborns to prevent tuberculosis. With over 80 million doses distributed annually, it is a cornerstone of public health efforts against TB in children. Recombinant TB Vaccine is set to record the highest CAGR in this split, 7.4% over 2026–2032. The Recombinant TB Vaccine is poised for rapid growth due to ongoing clinical trials aimed at introducing new vaccination options, reflecting a significant push towards advanced research in tuberculosis prevention. The Indian government's commitment to TB control and funding for vaccine development will further accelerate this segment's expansion. Suppliers should focus on increasing BCG Vaccine production while keeping an eye on the potential of emerging recombinant options.
By Formulation Type – Live Attenuated Dominated, Protein Subunit Expected to Grow Fastest
Live Attenuated took a 37% share of formulation type in 2025, more than any other category. Live Attenuated vaccines dominate the market as they are critical for effective TB vaccination programs, particularly for infants. Their established role in public health initiatives ensures a consistent demand across the country. Protein Subunit is projected to grow fastest, at a CAGR of 6.9% during 2026–2032. Protein Subunit vaccines are gaining traction as research progresses, indicating a potential shift in future vaccination strategies. The focus on these formulations aligns with global trends towards safer and more targeted vaccine options. Buyers should remain informed about advancements in Protein Subunit vaccines as they may offer new opportunities for TB prevention.
By Delivery Mode – Intradermal Injection Dominated, Clinical Trials Expected to Grow Fastest
In 2025, Intradermal Injection led the delivery mode split with a 35% share. Intradermal Injection is the leading delivery method for the BCG vaccine, ensuring effective administration for tuberculosis prevention in infants. Its established role in public health initiatives solidifies its position as the primary method of vaccine delivery in India. Over 2026–2032, Clinical Trials are expected to post the fastest growth, at a CAGR of 6.2%. Clinical Trials are crucial for the development of new vaccines, indicating a growing emphasis on research and innovation in TB vaccine delivery methods. The anticipated acceleration in this segment is linked to the testing and approval of new formulations. Suppliers must invest in research capabilities to support the transition towards innovative delivery methods in the TB vaccine market.
By End User – Public Health Programs Dominated, Biotech Firms Expected to Grow Fastest
Public Health Programs accounted for a 48% market share by end user in 2025. Public Health Programs are the predominant source of vaccine distribution, ensuring that the BCG vaccine effectively reaches the target population across India. Their role in national initiatives highlights the importance of government support in achieving high vaccination rates. The quickest growth will come from Biotech Firms, forecast to expand at a CAGR of 7.2% between 2026 and 2032. Biotech Firms are increasingly involved in research and development, driving growth as they explore new vaccine technologies and formulations. Their engagement suggests a shift towards more advanced solutions in tuberculosis prevention, which could reshape the market landscape. Suppliers should consider partnerships with biotech firms to leverage research advancements and enhance their market position.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- India Tuberculosis Vaccine Market Outlook
- Market Size of India Tuberculosis Vaccine Market, 2025
- Forecast of India Tuberculosis Vaccine Market, 2032
- Historical Data and Forecast of India Tuberculosis Vaccine Revenues & Volume for the Period 2022 - 2032F
- India Tuberculosis Vaccine Market Trend Evolution
- India Tuberculosis Vaccine Market Drivers and Challenges
- India Tuberculosis Vaccine Price Trends
- India Tuberculosis Vaccine Porter's Five Forces
- India Tuberculosis Vaccine Industry Life Cycle
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By Vaccine Type for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By BCG Vaccine for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By Recombinant TB Vaccine for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By DNA-Based Vaccine for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By mRNA Vaccine (R&D) for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By Formulation Type for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By Live Attenuated for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By Protein Subunit for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By Gene-Based for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By Messenger RNA for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By Delivery Mode for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By Intradermal Injection for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By Intramuscular Injection for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By Clinical Trials for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By Research Use Only for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By End User for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By Hospitals for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By Public Health Programs for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By Biotech Firms for the Period 2022 - 2032F
- Historical Data and Forecast of India Tuberculosis Vaccine Market Revenues & Volume By Pharma Researchers for the Period 2022 - 2032F
- India Tuberculosis Vaccine Import Export Trade Statistics
- Market Opportunity Assessment By Vaccine Type
- Market Opportunity Assessment By Formulation Type
- Market Opportunity Assessment By Delivery Mode
- Market Opportunity Assessment By End User
- India Tuberculosis Vaccine Top Companies Market Share
- India Tuberculosis Vaccine Competitive Benchmarking By Technical and Operational Parameters
- India Tuberculosis Vaccine Company Profiles
- India Tuberculosis Vaccine Key Strategic Recommendations
Market Covered
Segments analysed in this report are listed below.
By Vaccine Type
- BCG Vaccine
- Recombinant TB Vaccine
- DNA-Based Vaccine
- mRNA Vaccine (R&D)
By Formulation Type
- Live Attenuated
- Protein Subunit
- Gene-Based
- Messenger RNA
By Delivery Mode
- Intradermal Injection
- Intramuscular Injection
- Clinical Trials
- Research Use Only
By End User
- Hospitals
- Public Health Programs
- Biotech Firms
- Pharma Researchers
